Literature DB >> 2410448

Delayed type hypersensitivity to gangliosides in the Lewis rat.

H Offner, B A Standage, D R Burger, A A Vandenbark.   

Abstract

Systematic study of the immunologic properties of gangliosides has been hampered by the lack of a suitable assay. In this study, significant delayed type hypersensitivity reactions to gangliosides were observed in Lewis rats immunized with whole guinea pig spinal cord (GP-SC) in complete Freund's adjuvant (CFA). The reaction was manifested by an increase in ear thickness after intradermal injection of a mixture of gangliosides and methylated bovine serum albumin (mBSA). No responses were observed to either gangliosides or mBSA alone. The reaction to gangliosides increased after immunization, persisted for 48 h, and was characterized by perivascular infiltration of mononuclear cells. Further evidence for a cellular response was demonstrated by the transfer of ganglioside-specific ear swelling by cultured spleen cells. The response to gangliosides was not due to contamination with myelin basic protein (BP) since no reaction to gangliosides was observed in GP-BP/CFA-immunized rats, and no reaction to BP was observed in ganglioside/CFA-immunized rats. In BP-immunized rats, responsiveness to BP persisted after recovery from clinical EAE for at least 60 days. However, no response to gangliosides was observed in BP-immunized animals after recovery from clinical EAE, suggesting the lack of autosensitization to gangliosides due to the disease process itself.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410448     DOI: 10.1016/s0165-5728(85)80015-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  1 in total

1.  T cell determinants of myelin basic protein include a unique encephalitogenic I-E-restricted epitope for Lewis rats.

Authors:  H Offner; G A Hashim; B Celnik; A Galang; X B Li; F R Burns; N Shen; E Heber-Katz; A A Vandenbark
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.